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COMMENTARY
Molecular switches in signaling networks as a mechanism of action for oncogenic
mutations in proximity of tyrosine residues
Kristina B. Emdal a and Alicia Lundby a,b
aNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark;
bDepartment of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
ABSTRACT
We developed a mass spectrometry-based proteomics strategy to study oncogenic phosphotyrosine
signaling networks in tissues. We outlined epidermal growth factor-dependent phosphotyrosine signal-
ing in lung tissue and discovered that cancer mutations in vicinity of phosphotyrosine sites can induce
molecular switches in recruited protein complexes, which ultimately alter the signaling outcome of the
network activation.
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Tyrosine phosphorylation is a central post-translational mod-
ification that regulates multi-layered signaling networks.
Dysregulation of these networks is intricately involved in
cancer. Oncogenic mutations in the epidermal growth factor
receptor (Egfr) are, e.g., prevalent in lung adenocarcinomas,1
and tyrosine kinases have accordingly become prominent
anti-cancer drug targets.2,3 Functional investigations of the
molecular consequences of aberrant wiring of phosphotyro-
sine signaling in pathophysiological states remain experimen-
tally challenging, mainly due to the complexity of measuring
multiple signaling layers. To facilitate investigations of onco-
genic phosphotyrosine signaling networks, we recently devel-
oped a mass spectrometry-based proteomics strategy to
investigate such networks directly in tissue samples. We
applied the approach to study epidermal growth factor (Egf)-
dependent phosphotyrosine signaling in rat lung tissue and
outlined which phosphorylation sites are regulated as well as
which proteins are recruited to phosphorylated sites. In this,
we discovered that cancer mutations in vicinity of phospho-
tyrosine sites can induce molecular switches in recruited pro-
tein complexes that ultimately alter the signaling outcome of
the network activation.4 As a result, we presented molecular
switches in protein complex assembly at phosphotyrosine sites
as a mechanism of action for surrounding oncogenic muta-
tions (Figure 1(a)).
The immediate signaling response elicited by tyrosine
kinases induces changes in protein phosphorylation site stoi-
chiometry. Next, the succeeding signaling layer engages the
dynamical formation of protein-protein complexes at the
regulated phosphotyrosine sites. This recruitment of adaptor
proteins to phosphotyrosine sites is a critical part of the
signaling network as it wires an assembly of protein com-
plexes that each expands the signaling response. We
developed a mass spectrometry-based proteomics strategy to
resolve these two layers of phosphotyrosine signaling in tis-
sues: quantitative analysis of phosphotyrosine sites and sys-
tematic examination of the dynamically regulated protein
complexes they recruit. Phosphorylation site stoichiometry
changes can be analyzed by quantitative mass spectrometry-
based phosphoproteomics, which has previously been
achieved in tissue samples for the much more abundant
serine- and threonine-phosphorylation cascades.5,6,7 Analysis
of the less abundant, but functionally important, tyrosine
phosphorylation sites requires a separate enrichment strategy
based on phosphotyrosine-specific antibodies. With the
experimental strategy we developed, we additionally deter-
mine the identity of recruited protein complexes to phos-
phorylated tyrosine residues. Synthesizing peptides
corresponding to regulated phosphotyrosine sites and their
six flanking amino acids along with a biotin tag and
a hydrophilic linker, we use these peptides as baits in pull-
down experiments in tissue lysates (Figure 1(b)).4 Pulldowns
are performed in a 96-well format and interacting proteins are
enzymatically digested on-beads and subsequently analyzed
by high-resolution liquid chromatography–tandem mass spec-
trometry (LC-MS/MS).
With our approach, we depicted the Egf-dependent phos-
photyrosine signaling network in lung tissue and determined
the protein complexes assembled at Egf-dependent phospho-
tyrosine sites.4 It is well described, that adapter proteins are
recruited to phosphotyrosine sites through specificity granted
by the amino acid sequences surrounding the site.8,9 This led
us to ask, if the molecular consequence of cancer mutations
near phosphorylated tyrosine residues may be linked to
changes in protein complexes recruited to the phosphotyro-
sine site. We indeed confirmed this phenomenon. We found
that the lung cancer mutation Egfr P1019L induces a switch in
adaptor protein interactions at position pY1016, which leads
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to sustained activation of downstream kinase signaling path-
ways ultimately resulting in enhanced cell migration and
invasiveness.4 We identified another eight cancer mutations
in vicinity of phosphotyrosine sites and demonstrated that
their detrimental effect can alike be explained by the
introduction of molecular switches that alter protein signaling
networks. By detailed investigation of single amino acid can-
cer mutations located near regulated phosphotyrosine sites we
showed that these mutations induce a switch in the signaling
response by altering the recruitment of protein binding
Figure 1. Mechanisms whereby oncogenic mutations near phosphorylated tyrosine residues introduce molecular switches in signaling networks. (a) Oncogenic
mutations, such as P1019L (P; proline, L; leucine) and P1170S (S; serine) in epidermal growth factor receptor (Egfr), alter the protein complexes recruited to nearby
tyrosine (Y) residues (Y1016 and Y1172, respectively) compared to wild type Egfr, when these are phosphorylated. The wild type complex includes proteins Vav, Crk
and Crkl whereas mutant P1019L recruits proteins Sh2b1, Ship2 and Syk. Also, the protein complexes binding the phosphotyrosine site are tissue-specific as
exemplified for P1170S. The lung-specific complex includes Grb2, Grap2 and Shc1 whereas the liver-specific complex includes Stat1/4, Stat2 and Stat5b. Data from
a recently published paper by Lundby and colleagues.4 (b) Experimental investigation of recruited protein complexes is achieved by peptide-based pulldowns
exemplified for phosphorylated tyrosine-containing peptides (wild type and mutants as shown in (A)) and subsequent analysis by high-resolution mass spectrometry.
(c) From the mass spectrometry-based proteomics strategy the protein signaling networks are determined for wild type and oncogenic mutations near
phosphorylated tyrosine residues. The network components depend on the identity of the cancer mutations as well as tissue expression. (d) The molecular switches,
e.g., signaling networks alter the ultimate signaling outcome and hence may affect response to tyrosine kinase inhibitor (TKI) treatment. Knowledge of such altered
signaling activity may be used to generate personalized treatment strategies.
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partners to a completely different protein complex upon
receptor activation (Figure 1(c)). That is, we discovered
a concept of how oncogenic mutations in vicinity of phos-
photyrosine sites introduce a molecular switch that rewires
intracellular signaling cascades. This finding presents a new
mechanism linking dysregulated phosphotyrosine signaling to
cancer.
The methodology we developed illustrates how quantitative
phosphotyrosine interaction proteomics can be deployed to assign
novel functions to regulated phosphorylation sites in a large-scale
manner exemplified by Egf-signaling in rat lung tissue. We per-
formedmore than 1,000 peptide-based pulldowns in tissue lysates
and analyzed them using a ‘data-independent acquisition’ (DIA)
approach and cutting-edge mass spectrometry instrumentation
holding the potential to be applied to functionally evaluate patient
cancer mutations. To stress the potential of the technology in
a clinical context with regards to identifying altered signaling of
patient cancer mutants both at large scale and in a rapid fashion,
we streamlined themethodology to utilize the latest advancements
in mass spectrometry, which enables analysis of 60 peptide pull-
down experiments in just one day. Our finding of altered protein
complex signaling by cancer mutations suggests mutation-specific
possibilities for kinase inhibitor treatment strategies, e.g. to bypass
resistance to tyrosine kinase inhibitor (TKI) treatment (Figure 1
(d)). Investigation of these molecular switches allows for identifi-
cation of tissue-specific signaling pathway re-wiring induced by
cancer mutations, and has as such the potential to contribute to
tissue- andpatient-specific therapies. The outlook of the developed
strategy is an application in a clinical context where results can be
used to determine a strategy for personalized medicine for cancer
patients.
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